UNSPSC 51343822: Atazanavir/ritonavir

Definition: This classification denotes a combination drug for treatment of HIV. The first component, ATAZANAVIR is a protease inhibitor with a US FDA Unique Ingredient Identifier of QZU4H47A3S. ATAZANAVIR is an International Non-Proprietary Name or INN. The second component, RITONAVIR, is a pharmacokinetic booster with a US FDA Unique Ingredient Identifier of O3J8G9O825. RITONAVIR is an International Non-Proprietary Name or INN.

UNSPSC 51343822 Atazanavir/ritonavir is a Commodity code for antiretroviral pharmaceuticals used in HIV treatment, but the recent state and local procurement activity in the source contains no solicitations materially aligned with this code. The records reference pharmacy benefits programs, naloxone and drug deactivation systems, BLS/ALS emergency medical supplies, forensic drug standards, generic multi-source pharmaceuticals and OTC products, medical oxygen rental, and peer support services—none of which encompass HIV antiretroviral therapy or the specific fixed-dose combination of atazanavir and ritonavir. One opportunity (MMCAP generic pharmaceuticals) touches pharmaceutical procurement broadly but does not name or target antiretroviral agents.

Activity under this code does not register in the recent state and local procurement sample. No county, municipal, school district, transit authority, or state procurement office has posted a solicitation for atazanavir/ritonavir or a related class of HIV treatment pharmaceuticals in the records reviewed. The code remains inactive at the state and local level in this dataset, making pursuit timing assessment not yet viable from available opportunities.